Back to Cagrilintide research
cagrilintide amylin agonist rct n=234 2026-05-18 ClinicalTrials

Bioequivalence of Cagrilintide B + placebo semaglutide I and Cagrilintide D formulations to be assessed in overweight/obese adults

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Study Design

Population
234 adults with overweight or obesity.
Intervention
Cagrilintide B (with placebo semaglutide I) over 17 weeks.
Comparator
Cagrilintide D formulation.
Outcome
Blood levels of Cagrilintide B and Cagrilintide D.

Abstract

Phase 1 trial to compare Cagrilintide B (with placebo semaglutide I) and Cagrilintide D blood levels in 234 adults with overweight or obesity over 17 weeks.


cagrilintide semaglutide amylin agonist glp 1 agonist protocol relevant safety data present
Source: clinicaltrials:NCT07597018 · Ingested 2026-05-21 · Digest: gemini-2.5-flash